apomorphine has been researched along with Acute Confusional Senile Dementia in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bochar, DA; Deng, X; Dexheimer, T; Hovde, S; Kuo, MH; Kwok, R; Liu, M; Sui, D | 1 |
| Iinuma, KM; Imamura, T; Kira, JI; Murai, H; Nakamura, N; Ohyagi, Y; Soejima, N; Yamasaki, R; Yanagihara, YT | 1 |
| Miyoshi, K; Nakamura, N; Ohyagi, Y | 1 |
| Bakharev, B; Bobkova, N; Deev, A; Medvinskaya, N; Nesterova, I; Samokhin, A; Sengpiel, F; Tatarnikova, O; Ustyugov, AA; Vorobyov, V | 1 |
| Dargusch, R; Maher, PA; Schubert, D; Valera, E | 1 |
| Gordon, R; Kaptsov, V; Makarova, E; Podolski, I; Sengpiel, F; Vorobyov, V | 1 |
| Chen, W; Fu, X; Huang, L; Kong, X; Luo, Y; Pu, Z; Tang, H; Wei, S; Xing, H | 1 |
| Gandy, S; Steele, JW | 1 |
| Hashimoto, T; Himeno, E; Kira, J; LaFerla, FM; Ma, L; Miyoshi, K; Motomura, K; Nakamura, N; Ohyagi, Y; Sakae, N; Soejima, N; Tabira, T; Yamasaki, R | 1 |
| Ohyagi, Y | 2 |
| Ribarič, S | 1 |
| Aggarwal, A; Balakhaneh, D; Callaway, DJ; Hartley, DM; Lashuel, HA; Teichberg, S | 1 |
| Kira, J; Ma, L; Miyoshi, K; Motomura, K; Ohyagi, Y | 1 |
| Leiguarda, R; Merello, M; Migliorelli, R; Petracchi, M; Sabe, L; Starkstein, S; Teson, A | 1 |
| Crismon, ML; Dalmady-Israel, C; Fagan, SC; Gidal, BE; Graves, NM; Privitera, MD; Wagner, ML | 1 |
| Loopuijt, LD; Sebens, JB | 1 |
4 review(s) available for apomorphine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apomorphine; Diabetes Mellitus; Humans; Insulin; Insulysin; Mice | 2019 |
The pharmacological properties and therapeutic use of apomorphine.
Topics: Alzheimer Disease; Animals; Apomorphine; Dogs; Dopamine Agonists; Erectile Dysfunction; Female; Humans; Male; Parkinson Disease; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Substance-Related Disorders | 2012 |
[Molecular pathology and therapeutics in Alzheimer's disease: amyloid beta-protein as a therapeutic target].
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apomorphine; Enzyme Inhibitors; Humans | 2006 |
Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke.
Topics: Alzheimer Disease; Anticoagulants; Apomorphine; Aspirin; Cerebrovascular Disorders; Cholinergic Agents; Dopamine Agonists; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Platelet Aggregation Inhibitors; Tacrine | 1996 |
13 other study(ies) available for apomorphine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions.
Topics: Alzheimer Disease; Apomorphine; Benzodiazepines; Cognition; Drug Discovery; Drug Evaluation, Preclinical; Humans; Phosphorylation; Prescription Drugs; Protein Aggregates; Raloxifene Hydrochloride; Risk Factors; tau Proteins | 2020 |
Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer's Disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apomorphine; Disease Models, Animal; Dopamine Agonists; Exploratory Behavior; Gene Expression Regulation; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Insulysin; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phosphorylation; Presenilin-1 | 2017 |
Loss of Midbrain Dopamine Neurons and Altered Apomorphine EEG Effects in the 5xFAD Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Electroencephalography; Male; Mesencephalon; Mice; Mice, Transgenic | 2019 |
Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease.
Topics: Activating Transcription Factor 4; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apomorphine; Arachidonate 5-Lipoxygenase; Behavior, Animal; Blotting, Western; Curcumin; Dopamine Agonists; Electrophoresis, Polyacrylamide Gel; Eukaryotic Initiation Factor-2; Humans; Lipoxygenase Inhibitors; Maze Learning; Mice; Mice, Transgenic; Peptide Fragments; Phosphorylation; Proteasome Endopeptidase Complex; Protein Folding; Pyrazoles; RNA, Messenger; Ubiquitin | 2013 |
Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Apomorphine; Cerebral Cortex; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrodes, Implanted; Electroencephalography; Fullerenes; Hippocampus; Male; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Time Factors | 2015 |
Oxoisoaporphine alkaloid derivative 8-1 reduces Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Apomorphine; Benzodioxoles; Caenorhabditis elegans; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Oxidative Stress; Peptide Fragments; Phthalazines | 2017 |
Apomorphine and Alzheimer Aβ: roles for regulated α cleavage, autophagy, and antioxidation?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apomorphine; Autophagy; Dopamine Agonists; Mice; Oxidative Stress | 2011 |
Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apomorphine; Blotting, Western; Brain; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Immunohistochemistry; Insulysin; Maze Learning; Memory, Short-Term; Mice; Mice, Transgenic; Neprilysin; Neurons; Oxidative Stress; Phosphorylation; Proteasome Endopeptidase Complex; Statistics, Nonparametric; tau Proteins | 2011 |
[A drug targeting intracellular amyloid-β and oxidative stress: apomorphine].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apomorphine; Dopamine Agonists; Drug Delivery Systems; Mice; Oxidative Stress | 2011 |
New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apomorphine; Benzothiazoles; Fluorescent Dyes; Humans; Hydroxylation; Kinetics; Microscopy, Electron; Models, Biological; Protein Structure, Quaternary; Thiazoles | 2002 |
[Inhibition of neuronal death by promoting degradation of intracellular amyloid beta-protein].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apomorphine; Apoptosis; Humans; Neurons; Proteasome Endopeptidase Complex; Tumor Suppressor Protein p53 | 2007 |
Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates.
Topics: Aged; Alzheimer Disease; Apomorphine; Case-Control Studies; Dementia; Depressive Disorder; Extrapyramidal Tracts; Female; Humans; Interview, Psychological; Male; Neuropsychological Tests; Parkinson Disease, Secondary; Prevalence; Severity of Illness Index | 1994 |
Loss of dopamine receptors in the olfactory bulb of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apomorphine; Autoradiography; Brain; Dopamine Agents; Female; Humans; Male; Middle Aged; Olfactory Bulb; Organ Size; Receptors, Dopamine; Receptors, Dopamine D2; Tritium | 1990 |